INTRODUCTION
Studies of the roles of the hematopoietic microenvironment have markedly increased in recent years, primarily due to the identification of the bone-forming osteoblast as being a critical component of the hematopoietic stem cell (HSC) niche, the place where HSCs reside and are primarily regulated (Calvi et al., 2003; Zhang et al., 2003) . In addition to this important role in regulating HSC self-renewal and differentiation, the bone marrow (BM) microenvironment has been proposed to consist of various other niches, first termed hematopoietic inductive microenvironments (Trentin, 1971) , which are areas of the BM that are highly specialized for the development of different maturing hematopoietic cell types. This concept has been supported by the recent identification of specific niches for B lymphocytes (Tokoyoda et al., 2004) and megakaryocytes (Avecilla et al., 2004) in the BM.
The hematopoietic microenvironment is not only supportive for the development of hematopoietic cells but is also known as a highly preferred site for the metastasis of certain cancer cell types, including breast, prostate, and melanoma cancers. A recent report demonstrated that the cytokine receptor activator of NF-kB ligand (RANKL), a member of the tumor necrosis factor (TNF) family of cytokines, and which is expressed by osteoblasts, recruited epithelial and melanoma cancer cells expressing RANK to the BM, where they subsequently lodged and formed secondary tumors (Jones et al., 2006) . A similar chemoattractant role for nonhematopoietic cancer cells has been described for the chemokine, CXCL12 (Muller et al., 2001) , which is also expressed by osteoblasts and is known to be an important mediator of the homing of HSCs to the BM (Lapidot et al., 2005) . Despite these recent advances, however, virtually nothing is known about the potential involvement of the BM microenvironment in the initiation of different diseases of hematopoietic origin, or the underlying factors that influence the development of these disorders.
Myeloproliferative syndromes (MPS) are a heterogeneous subclass of nonlymphoid hematopoietic neoplasms for which, with the exception of chronic myeloid leukemia (CML), hypereosinophilic syndrome, and juvenile myelomonocytic leukemia, the causes remain largely unknown (Van Etten and Shannon, 2004) . To date, MPS have been considered to be of hematopoietic origin (Kogan et al., 2002) , and the involvement of Bcr-Abl in CML (Van Etten and Shannon, 2004) together with various studies utilizing mouse models support this hypothesis (Araki et al., 2004; Le et al., 2004; Passegue et al., 2004; Wernig et al., 2006; Yan et al., 1994) . Despite this, the molecular basis of a significant subset of other MPS, such as myelofibrosis and myelodysplastic syndrome (MDS), remains unknown. Likewise, it is unclear as to whether the hematopoietic (BM) microenvironment may play an active part in promoting and/or supporting the development of MPS.
Retinoic acid receptors (RARs) have been associated with many different diseases, including cancer, and retinoid-based therapies are increasingly being utilized to treat such disorders (Altucci and Gronemeyer, 2001 ). There are three RAR subtypes: RARa, RARb, and RARg, all of which are highly conserved amongst species. The vitamin A derivative, all-trans retinoic acid (ATRA), is the naturally occurring ligand for all RARs.
The RARs are nuclear hormone receptors that act as ligand-dependent transcriptional regulators; in their liganded state, they activate transcription, whereas in the nonliganded form, they repress transcription of their target genes (Minucci and Pelicci, 1999) . RARs have numerous direct target genes which have retinoic acid response elements in their promoter region Blomhoff, 2002, 2005) .
The generation of RAR-specific mutant mice has allowed delineation of the different roles of the RARs in organogenesis. We have recently shown that RARg, but not RARa, null mice have 3-fold reduced numbers of hematopoietic stem cells (HSCs) (Purton et al., 2006) . Here, we show that loss of RARg also results in a myeloproliferative-like disease. This MPS was not intrinsic to the hematopoietic cell, but was induced by the RARg null microenvironment. These novel findings reveal that the microenvironment can play a dominant role in both inducing and supporting the progression of hematopoietic diseases such as MPS and potentially leukemias.
RESULTS

Loss of RARg Results in Perturbed Hematopoiesis with Significantly Elevated Granulopoiesis
We have observed that RARa and RARg, but not RARb isoforms are widely expressed in immature and maturing hematopoietic cell types (Purton et al., 2006; and unpublished data) . Furthermore, the natural ligand for RARs, ATRA, has potent effects on enhancing HSC self-renewal and promoting differentiation of more mature granulocyte/ macrophage progenitors, which we have previously demonstrated are likely due to the different actions of RARa and RARg on hematopoietic cells (Purton et al., 1999 (Purton et al., , 2000 (Purton et al., , 2006 . RARa À/À mice do not have any observable hematopoietic defects in vivo (Kastner et al., 2001; Purton et al., 2006) , whereas RARg À/À mice have significantly reduced numbers of HSCs accompanied by increased numbers of immature progenitor cells in their BM (Purton et al., 2006) . To determine if loss of RARg also affected the production of mature hematopoietic cells, we examined the cellularity and hematopoietic composition of peripheral blood (PB), BM, spleen, and thymus preparations obtained from RARg null, heterozygous, and wildtype mice. Eight-week-old RARg À/À mice had significantly elevated PB and BM leukocytes compared to their wildtype littermates ( Figure 1A ). The elevated leukocyte levels were comparable to those achieved by oncoretroviral overexpression-induced models of MPD in C57Bl/6 background strains (Wernig et al., 2006) . Spleen leukocyte numbers were also elevated in RARg À/À mice, but this increase was not significant compared to the wild-type mice. Eight-week-old RARg À/À mice also presented with splenomegaly, with spleen weights significantly increased (1.5-to 3-fold) compared to their wild-type littermates. In contrast, the thymic cellularity was significantly reduced (25%) in RARg À/À mice compared to their wild-type littermates ( Figure 1A ). RARg À/À mice have a growth deficiency (Lohnes et al., 1993) , and at 8 weeks of age were approximately 20% smaller than their wild-type littermates (Table S1 in the Supplemental Data available with this article online). When normalized to body size, the thymocyte cellularity was similar to that of wild-type mice; however, there were significant increases in BM and spleen cellularity in RARg À/À mice. We used immunophenotypical analysis to further explore the effects of loss of RARg on the production of mature hematopoietic cell lineages. There were marked increases in the numbers of CD11b+ Gr-1+ granulocytes in the PB (Figure 1B and Table S2 ), BM ( Figure 1C and Table S2), and spleen ( Figure 1D and Table S2 ) of RARg À/À mice compared to their wild-type littermates. These increases occurred in both the immature and mature granulocyte compartments in the BM (Walkley et al., 2002) ( Figure 1C and Table S2 ).
There were also significant reductions in the numbers of B lymphocyte subsets and erythrocytes in the BM of the RARg À/À mice (Tables S1 and S2) ; however, the numbers of these cells were unaltered in the PB and spleen (Table S1 ). In contrast to RARg À/À mice, RARg +/À mice did not have altered numbers of mature hematopoietic cells ( Figure 1 and Table S1 ).
The Increased Granulocyte Compartment in RARg Null Mice Arises at an Immature Progenitor Level
We further focused on investigating the mechanisms behind the increased granulopoiesis in the RARg À/À mice. Both the immature (CD11b+ Gr-1 dim) and mature (CD11b+ Gr-1 bright) granulocyte subsets were significantly elevated in the BM, suggesting that the increase in granulocytes was arising from an immature progenitor population (Walkley et al., 2002) . Furthermore, we have recently shown that RARg À/À mice have increased numbers of immature colony-forming cells (CFU-GEMM), which likely arise from accelerated differentiation of HSCs into progenitor cells (Purton et al., 2006) . We therefore investigated the numbers of more committed granulocyte progenitors in the BM of RARg
The numbers of day 7 GM-CSF, SCF+G-CSF, and G-CSF-responsive colony-forming cells (CFCs) were significantly increased in RARg À/À BM compared to that of wild-type littermates (Figures 2A and 2B ). The numbers of more mature day 3 cluster-forming cells were also significantly increased in these mutants compared to wildtype mice ( Figure 2C ). The PB and spleen of RARg À/À mice also had increased numbers of mature myeloid CFCs (CFU-GM) ( Figures 2C and 2D ), but the numbers of immature CFCs (CFU-GEMM) and immunophenotypic HSC/progenitor cells in these organs were not significantly different to RARg +/+ mice (Table S3 ). These data demonstrated that there were increased numbers of committed myeloid progenitors in the BM, spleen, and PB of RARg À/À mice. In contrast, the lack of CFU-GEMM and HSC/progenitor cells in spleen and PB suggested that RARg À/À mice were not presenting with an HSC mobilization phenotype.
To determine if the increased numbers of progenitors could be due to altered cytokine sensitivity, we investigated the numbers of BM CFCs formed in submaximal and supramaximal concentrations of G-CSF (Walkley et al., 2002) . Both RARg À/À and RARg +/+ BM cells showed a similar cytokine response, hence it did not appear that the progenitor cells had altered sensitivity to cytokines ( Figure 2F ). A similar result was also observed in response to IL-3 (unpublished data). It was possible that the increased numbers of CFCs were due to increased survival of these progenitors. To assess this, we established CFC assays and delayed cytokine addition to 24 and 48 hr. The numbers of CFCs that formed were then assessed at 7 days postinitiation. There were no differences in the survival of progenitors stimulated with G-CSF ( Figure 2G ), suggesting that the myeloid expansion was not a secondary response due to altered cell death of granulocyte progenitors. Finally, we assessed the frequencies of common myeloid progenitors (CMP), granulocyte/macrophage progenitors (GMP), and megakaryocyte/erythroid progenitors (MEP) in RARg À/À and RARg +/+ BM (Akashi et al., 2000) . The frequency of GMPs was significantly increased (1.8-fold) in RARg À/À BM compared to that of their wildtype littermates ( Figure 2H ). Given that RARg À/À mice also had significantly increased BM leukocyte cellularity compared to RARg +/+ mice ( Figure 1A ), this resulted in an overall significant 2.1-fold increase in absolute numbers of GMPs in RARg null BM compared to wild-type BM.
RARg Null Granulocytes Have Normal Functional Potential
The elevated granulopoiesis in RARg À/À mice could be compensatory if these cells had impaired functional capacity, hence we tested several of their functional properties. The oxidative bursts response was similar in BM samples of either genotype ( Figure S1 ). Furthermore, recruitment of cells after intradermal injection of Zymosan A (which elicits an acute inflammation response) was similar in RARg À/À mice compared to their wild-type littermates ( Figure S1 ), and there was no difference between the morphology of the cell types that were recruited to the ear in response to Zymosan A (data not shown). Finally, there was no difference in the percentage of BM granulocytes undergoing apoptosis when assessed by annexin V staining ( Figure S1 ). These data suggested that RARg À/À granulocytes had similar functional potential to those of RARg wild-type granulocytes.
Aging RARg Null Mice Have a Profound Myeloproliferative-Like Disease with Excessive Extramedullary Hematopoiesis
We have recently reported that small numbers of RARg À/À mice survive to approximately 12 months of age (Purton et al., 2006) . To determine if the increased granulocyte phenotype persisted for the lifespan of RARg À/À mice we investigated the cellularity and hematopoietic composition of different organs obtained from 12-month-old RARg À/À and RARg +/+ mice. The average PB leukocyte counts of the older RARg À/À mice were dramatically increased compared to their wildtype littermates (RARg +/+ = 10.54 ± 0.51; RARg À/À = 29.6 ± 3.32 3 10 3 /ml blood, p < 0.005). This was accompanied by significantly increased numbers of granulocytes in the PB, spleen and BM ( Figures 3A-3C ). Platelets were also significantly elevated in the PB of these older knockout Results are expressed as mean ± SEM, n = 4 (A-C), n = 3 (D-H). *p < 0.05, #p < 0.005 compared to RARg +/+ (Student's t test).
mice (RARg +/+ = 1480 ± 46.7; RARg À/À = 1888 ± 66.7 3 10 3 /ml blood, p < 0.005). In contrast, erythrocyte numbers were significantly reduced in the PB of these aged mutant mice (RARg +/+ = 9.77 ± 0.32; RARg À/À = 8.87 ± 0.15 3 10 6 /ml blood, p < 0.05).
Analysis of immature progenitors in these mice revealed that RARg À/À mice had significantly increased numbers of CFU-GEMM and CFU-GM in their PB and spleen ( Figures 3D, 3F , 3G, and 3I), accompanied by strikingly elevated numbers of lineage-restricted granulocyte/ macrophage CFCs in their bone marrow (Figures 3E and 3H) . Significantly reduced numbers of mature B cells and erythrocytes were also observed in the bone marrow of the 12-month-old RARg À/À mice ( Figure 3J ).
The frequencies of the lineage-negative, c-kit-positive, Sca-1-negative (LKSÀ) progenitor cells were significantly increased in BM and spleens of 12-month-old RARg À/À mice (Table S4 ). The HSC-containing lineage-negative, c-kit-positive, Sca-1+ (LKS+) cells were also markedly elevated in the spleens of these mice (Table S4) .
Histological analysis of different organs of 9-to 12-month-old mice revealed that the bone marrow of the RARg À/À mice was extremely hypercellular compared to their wild-type littermates ( Figures 4A and 4B ). The trabecular bones were virtually absent, and the cortical bones were dramatically thinner in these older RARg À/À mice ( Figure 4B ). Bone marrow cells of the RARg À/À mice were predominantly developing myeloid cells, with some megakaryocytes also obvious ( Figures 4B and 4D ). Reduced B lymphocyte foci were also evident in the spleens of the RARg À/À mice compared to their wildtype littermates ( Figure S2 ). Myeloperoxidase staining revealed that extramedullary hematopoiesis was occurring in the liver of the RARg À/À mice, however we did not observe significant numbers of hematopoietic cells in their kidneys compared to their wild-type littermates ( Figure S2 ). Strikingly, there were large foci of immature and maturing hematopoietic cells (including granulocytes, monocytes, megakaryocytes, and erythrocytes) developing in adipose tissue in these older of the RARg À/À mice, Results are expressed as mean ± SEM, n = 4-8 (A-C, J), n = 3 (D-I). *p < 0.05, #p < 0.005 compared to RARg +/+ (Student's t test).
but not in their wild-type littermates ( Figures 4E-4H ). During their lifespan, however, none of the animals developed leukemia or lymphoma. Given the significantly increased myeloid compartment in the mice with tissue infiltration, together with lack of evidence of malignant transformation, the phenotype of the RARg À/À mice best corresponds with that of a myeloproliferative-like disease (MPD-like, or MPS) (Kogan et al., 2002) .
The Myeloproliferation in RARg Null Mice Is Not Intrinsic to the Hematopoietic Compartment but Is Induced by the RARg Null Microenvironment
Myeloproliferative-like diseases are thought to arise from hematopoietic cells (Kogan et al., 2002) . In a previous study, we investigated the HSC frequency in the RARg À/À BM (Purton et al., 2006) . During the 6 months of monitoring recipient mice posttransplant, we did not observe a MPS in wild-type mice that were transplanted with BM from the RARg À/À mice. However, these transplants were performed with competing BM from wild-type congenic mice, which may have masked or prevented the occurrence of the myeloproliferation. Therefore, we repeated the transplants using whole BM without competing cells and compared the hematopoietic phenotypes to that of 8-week-old RARg null mice (Figures 5A and 5B) . In contrast to the MPS observed in RARg À/À animals, at 8 weeks posttransplant all wild-type recipients of either RARg +/+ or RARg À/À BM had similar PB leukocyte and granulocyte counts ( Figures 5C and 5D ). The PB cellularity did not increase during the 6 months the mice were monitored posttransplant (at 6 months Table  S5 ). The increases in leukocytes and granulocytes were even more profound compared to 8-week-old nontransplanted RARg À/À mice ( Figures 5A and 5B, Table S2 ).
Immunophenotypical analysis confirmed the hematopoietic cells were of wild-type origin rather than endogenous recovery of RARg null hematopoietic cells. In addition to the markedly elevated granulocytes in these transplant recipients, BM B lymphopoiesis and erythropoiesis were also significantly suppressed when the wild-type congenic BM was transplanted into the RARg À/À mice ( Figure 5G , Table S5 ). This was also more profound compared to the B lymphocyte and erythrocyte phenotype observed in the BM of 8-week-old RARg À/À mutants (Tables S1 and S2 ). Hence, the myeloproliferative-like disease observed in RARg À/À mice was not intrinsic to the hematopoietic cells, but was induced by the RARg deficient microenvironment.
The RARg-Deficient Microenvironment Has Normal HSC Niche Potential We have previously reported that 8-week-old RARg À/À mice have 3-fold reduced numbers of HSCs accompanied by increased numbers of progenitors, including day 12 colony-forming unit-spleen (CFU-S) (Purton et al., 2006) . Given that the trabecular bone has been described as being a key component of the HSC niche (Calvi et al., 2003; Zhang et al., 2003) and that trabecular bone was virtually absent in 12-month-old RARg À/À mice ( Figure 4B ), we wished to determine whether the microenvironment of 8-week-old RARg À/À mice was impaired in its ability to support HSCs.
Histological sections of undecalcified tibiae revealed significantly reduced trabecular bone in 8-week-old RARg À/À mice. Histomorphometric quantitation of the tibiae sections from RARg À/À mice demonstrated significantly fewer and more dispersed trabeculae, decreased trabecular volume but normal trabecular thickness in tibiae obtained from RARg À/À compared to wild-type mice (L.E.P. and N.A. Sims, unpublished data). This resulted in an overall 1.6-fold reduction in the number of trabeculae in these mice. Despite this, there were similar percentages of osteoblasts per bone surface in 8-week-old RARg À/À mice compared to wild-type mice. In contrast, the reduction in trabecular bone was accompanied by 1.6-fold increased numbers of osteoclasts per bone surface, indicating increased osteoclastogenesis was the predominant cause of the osteopenia in 8-weekold RARg À/À mice (L.E.P. and N.A. Sims, unpublished data). To assess whether this reduction in trabecular bone impaired HSC self-renewal, we transplanted lethally irradiated RARg +/+ or RARg À/À recipient mice with wild-type congenic BM. At 8 weeks posttransplant (a similar time of exposure to the niche as that of the 8-week-old mutants used in our previous studies [Purton et al., 2006] ), we assessed the numbers of CFCs, CFU-S, and HSCs (using the limiting dilution assay) in the transplanted mice as previously described (Purton et al., 2006; Szilvassy et al., 1990; Walkley et al., 2005) . The numbers of CFU-GM were significantly increased in PB and spleen, but not BM of RARg À/À recipient mice ( Figures S3A-S3C ). In contrast, there were no differences in the numbers of CFU-GEMM, LKS+, CFU-S, or HSCs when wild-type BM was exposed to an RARg À/À microenvironment compared to an RARg +/+ niche (Figures S3D-S3H ). In vitro coculture assays revealed that RARg À/À stromal cells increased the production of maturing wild-type BM cells during 14 days of culture ( Figure S3I ). Collectively, these data suggest that the RARg À/À microenvironment increases the proliferation and production of relatively mature hematopoietic cells but does not affect the numbers of immature progenitors and HSCs.
Loss of RARg Results in Markedly Increased Production of TNFa
In order to further elucidate the mechanisms behind the myeloproliferation in the RARg À/À mice, we examined the expression of different inflammatory mediators, myeloid cytokines, and JunB, which is a putative target of retinoic acid (Balmer and Blomhoff, 2002) , and induces an MPD (Passegue et al., 2004) , in the hematopoietic organs of the RARg mutants.
The expression of TNFa was significantly increased in all three hematopoietic organs in RARg À/À mice compared to their wild-type littermates ( Figure 6A ). In contrast, expression of other proinflammatory cytokines, IL-2 and IL-6 were not markedly altered in the organs (Table S6 ). The expression of IL-4 was significantly reduced in the BM and slightly but significantly elevated in the spleen of RARg À/À mice (Table S6 ).
The expression of JunB was not altered in the BM (Table  S6) . Neither of the two major myeloid cytokines, GM-CSF or G-CSF, were elevated in any organ (Table S6 ). In contrast, G-CSF expression was significantly reduced in the thymus of RARg À/À mice compared to their wild-type littermates ( Table S6 ). Given that we had not observed altered numbers of T lymphocyte subsets in RARg À/À mice (Table S1 ), we further investigated the expression of TNFa in purified populations of T lymphocytes. TNFa was predominantly expressed by thymocytes expressing CD4 and/or CD8 (Table S6) , consistent with a previous report investigating the synthesis of TNFa by T lymphocyte populations (Giroir et al., 1992) . TNFa is a proinflammatory cytokine that is known to reduce the numbers of B lymphocytes in the BM and preferentially promote granulopoiesis via reductions in CXCL12 expression in BM (Ueda et al., 2004 (Ueda et al., , 2005 . CXCL12 was unaltered in RARg À/À BM and spleen, and was elevated in the thymus (Table S6) . Hence, the reduced B lymphopoiesis observed in RARg À/À BM (Table   S1 ) did not appear to be a result of reduced CXCL12 expression that normally occurs in the BM during inflammation. Figure 6B ). The numbers of BM leukocytes were not altered (data not shown), whereas the spleen leukocyte counts were restored to the levels of the wild-type transplant recipients ( Figure 6F ). While still elevated above that of wild-type recipients, the fold-increases in granulocytes in all organs were reduced by approximately 50% in BM and spleen, and were 3-fold reduced in PB of RARg À/À mice transplanted with TNFa À/À BM compared to those transplanted with wild-type BM ( Figures 6C, 6E , 6G, and S4). The numbers of B220+/IgM+ cells remained significantly lower in the BM of RARg À/À recipients transplanted with TNFa À/À BM; however, the numbers of immature B220+/ IgM-cells in these recipients were restored to that of wild-type recipients ( Figure 6H ). Finally, BM erythropoiesis in RARg À/À recipients transplanted with TNFa À/À BM was restored to the levels observed in wild-type recipients ( Figure 6H ). These data indicate that deregulated TNFa production significantly contributes to, but is not the sole cause of, the myeloproliferative-like disease that is induced by the microenvironment of RARg null mice.
Absolute Requirement of an RARg Null Microenvironment to Sustain the Myeloproliferation
Approximately one-third of the RARg À/À recipients had PB leukocyte counts above 48 3 10 6 cells/ml (twice that normally achieved by oncoretroviral MPD in a C57BL/6 background) at 8 weeks posttransplant and had to be euthanized due to poor condition. These mice also had severe anemia, reflected by significantly reduced PB erythrocyte counts and hemoglobin content (data not shown). PB smears of these recipient mice revealed highly elevated numbers of circulating immature myeloid cells and numerous abnormal erythrocytes in the RARg À/À recipients compared to the wild-type recipients ( Figures  7A and 7B ). FACS analysis confirmed the cells in both recipient types were of wild-type donor origin (Figures 7C and 7E) , and showed that the majority (74.9 ± 1.89%, n = 3) of the PB leukocytes in the RARg À/À recipients were immature myeloid cells coexpressing intermediate levels of Gr-1 and CD11b ( Figure 7F ). In contrast, the same donor cells transplanted into a wild-type microenvironment had PB content of approximately 15.1 ± 1.55% cells (n = 4) expressing higher levels of Gr-1 and CD11b ( Figure 7D ). To determine if leukemic transformation of the cells had occurred, we transplanted whole spleen cells consisting Transplant data are shown at 5-8 weeks posttransplant, n=4-6 recipients/group. of 2.5 3 10 6 leukocytes (containing 25% immature granulocytes by FACS) from one such primary RARg À/À recipient ( Figures 7B, 7E , and 7F) into lethally irradiated wild-type and RARg À/À secondary recipient mice and monitored their recovery during 8 weeks posttransplant.
At 8 weeks posttransplant, the average CD45.1+ donor reconstitution was similar between groups (approximately 80%, data not shown). Surprisingly, the MPD-like phenotype was highly dependent upon the secondary recipient genotype, demonstrating that the hematopoietic cells had not undergone leukemic transformation during the primary transplant. When injected into wild-type secondary recipients, the percentage of donor-derived granulocytes at 8 weeks posttransplant reverted to 26.6 ± 6.36% (n = 5), with many mature granulocytes evident ( Figures 7G and 7H) . In marked contrast, when injected into RARg À/À recipients the splenic leukocytes reconstituted an average of 78.87 ± 9.31% immature granulocytes in the PB of these recipients ( Figures 7I and 7J , n = 5, p < 0.003 wild-type versus RARg À/À recipients). These data therefore revealed that an RARg null microenvironment was absolutely required to maintain the MPS. (E and F) FACS analysis of the RARg À/À recipient shows high levels of donor cell reconstitution (E) and abnormal granulocyte profiles (F) in the PB.
(G and H) Two representative FACS profiles of donor-derived PB granulocytes in secondary RARg +/+ recipients transplanted with 2.5 3 10 6 spleen leukocytes obtained from the primary RARg À/À recipient whose PB parameters are shown in (B), (E), and (F).
(I and J) Two representative FACS profiles of donor-derived PB granulocytes in secondary RARg À/À recipients transplanted with 2.5 3 10 6 spleen leukocytes obtained from the primary RARg À/À recipient whose PB parameters are shown in (B), (E), and (F).
Data are shown at 8 weeks posttransplant, n = 3-5 recipients/group.
DISCUSSION
Loss of RARg Results in a Myeloproliferative Syndrome
Our studies show that loss of one of the major receptors for vitamin A, RARg, results in a microenvironmentinduced MPS. The myeloproliferation likely arises from the GMPs in the bone marrow and progresses markedly with age. Profound loss of trabecular bone in 12-monthold mice correlated with marked increases in the numbers of immature CFCs detectable in PB and spleen and extramedullary myelopoiesis in other organs including liver and adipose tissue. The microenvironment-induced myeloproliferation partially involves elevated TNFa expression, as transplantation of TNFa À/À BM into RARg À/À mice markedly ameliorated the MPD-like phenotype. However, we did not observe any evidence of progression to leukemia during the lifespan of these mice. Furthermore, the RARg À/À microenvironment was absolutely required to sustain the MPS, as the phenotype reverted when either BM ( Figures 5C and 5D ) or spleen cells (Figures 7G and 7H) from RARg À/À mice were transplanted into wild-type
recipients. An interesting observation in the older RARg À/À mice was the hematopoietic support potential of the adipose tissue in these mice. Adipocytes are present in bone marrow, albeit in low numbers in mice. Several previous reports have suggested that adipocytes and adipose tissue are capable of supporting hematopoiesis, including myelopoiesis (Corre et al., 2004; Cousin et al., 2003; Hangoc et al., 1993) . Leptin, a hormone produced by adipocytes, has been shown to augment myeloid colony formation (Bennett et al., 1996) . In addition, the leptin receptor has been shown to be expressed by immature myeloid cells (Gainsford et al., 1996) . Adiponectin, another protein expressed by adipocytes, has also been linked to the regulation of immature myeloid cells, however, it has been described as being a negative regulator of these progenitors (Yokota et al., 2000) . Interestingly, TNFa has been shown to increase leptin and reduce adiponectin expression in adipose tissue (Vettor et al., 2005) , hence it is possible that increased TNFa signaling directly enhanced the hematopoietic support potential of adipose tissue in the older RARg null mice. Regardless of the mechanism, it appears that under conditions of extreme hematopoietic stress, adipose tissue can serve as an additional organ capable of supporting extramedullary hematopoiesis.
A previous study also showed that vitamin A deficiency (VAD) in mice resulted in myeloproliferation (Kuwata et al., 2000) . The VAD mice did not show external signs of infections, and sera screening and cytokine analysis of these mice did not reveal any infectious cause of the myeloproliferation (Kuwata et al., 2000) . This MPD-like phenotype took approximately 14 weeks to become evident and was more profound than that we have observed in nontransplanted RARg À/À mice (Figure 1 ) but less severe than we have observed in approximately 1/3 rd of RARg À/À recipients transplanted with wild-type congenic BM (Figures 6B, 6E, and 6F) . When the VAD mice were fed a vitamin A supplemented diet, their granulocyte phenotype was reversed (Kuwata et al., 2000) . Although there are similarites in the studies performed by Kuwata et al. (2000) to ours, there are also distinct differences. The numbers of B220+ cells were unaltered in the BM of VAD mice compared to those a fed vitamin A-supplemented diet. In contrast, we observed a dramatic reduction in the numbers of B lymphocytes in mice that had an RARg null microenvironment. Furthermore, unlike our findings, the numbers of colonies that formed from BM from VAD mice were not significantly increased compared to BM from mice fed the supplemented diet. Instead, the increased granulocytes were found to result, at least in part, to impaired apoptosis in the granulocytes of VAD mice (Kuwata et al., 2000) . We did not observe altered granulocyte apoptosis in our studies ( Figure S1 ).
A similar elevated granulocyte phenotype to the one observed in RARg À/À mice was also observed when mice were fed a pan-RAR antagonist for 10 days (Walkley et al., 2002) . Like that of RARg À/À mice, this increase was accompanied by increased numbers of granulocyte progenitors and was not due to altered survival properties of granulocytes or their progenitors. Vitamin A activates both the RARs and the retinoid X receptors (RXRs), which form heterodimers with both RARs and other members of the steroid hormone super family to activate transcription. It is therefore likely that some of the defects observed in VAD mice, including impaired apoptosis of granulocytes were due to loss of RXR function. Our studies show, however, that the increased numbers of granulocytes observed in VAD mice were likely due, at least in part, to loss of RARg function, and were not intrinsic to the hematopoietic cell.
TNFa is classically known as a proinflammatory cytokine, which raises the possibility that the myeloproliferation observed in RARg null mice results from an inflammatory process. However, the markedly elevated TNFa expression we observed was not accompanied by increases in other cytokines normally associated with inflammation (IL-2, IL-6, or IL-4 [ Table S6 ]), nor was the expression of IFNg deregulated (data not shown). Furthermore, there was no evidence of infection in RARg À/À mice or in the VAD mice studied by Kuwata et al. (Kuwata et al., 2000) , and the myeloproliferation also occurred in RARg À/À mice that were administered antibiotics from the time of weaning to analysis.
Emerging Evidence for Roles of the Microenvironment in Inducing MPS
Myeloproliferative syndromes have, to date, been considered to be hematopoietic cell intrinsic. Studies utilizing either transgenic mice such as JunB (Passegue et al., 2004) , Ptpn11 (Araki et al., 2004) or Nf1 (Le et al., 2004) , or oncoretroviral overexpression of acquired somatic mutations such as Jak2V617F (Wernig et al., 2006) have demonstrated that some MPS are intrinsic to the hematopoietic cell. However, given that the BM microenvironment is known to be an important regulator of hematopoiesis it is not unreasonable to speculate that the microenvironment may play a larger role in the development of MPS than previously thought. Our data and that of Walkley et al. (2007 [in this issue of Cell] ) support this possibility.
Indeed, another recent study has provided additional support to the potential role of the microenvironment in regulating MDS. Conditional germline deletion of the inhibitor of NF-kB (IkBa) resulted in hypergranulopoiesis that was not cell autonomous (Rupec et al., 2005) . Loss of IkBa also resulted in increased numbers of dysplastic hematopoietic cells (erythrocytes, megakaryocytes, and granulocytes), resulting in MDS with progression to secondary acute myeloid leukemia (Rupec et al., 2005) . The mice died between 6 and 7 days after birth. Additional studies in this report showed that Notch1 was upregulated in IkBa D/D granulocytes, and the Notch1 ligand, Jagged1, was shown to be upregulated in IkBa D/D hepatocytes (Rupec et al., 2005) . Inhibition of Jagged1 was able to abolish the hypergranulopoiesis that occurred when wild-type BM cells were cocultured with IkBa D/D hepatocytes (Rupec et al., 2005) . It is unclear, however, whether the nonhematopoietic microenvironment in the IkBa D/D mice was the sole contributing factor to the myelodysplastic syndrome and subsequent progression to leukemia observed in IkBa D/D mice, or whether, like that demonstrated in the accompanying paper by Walkley et al. (2007) (Szlosarek et al., 2006) . Here, we provide the first demonstration that an abnormal microenvironment created by RARg deficiency can be the sole causative mechanism for MPS. These data provide further support for evaluating the bone marrow microenvironment as a source of hematologic disease and potential target for future therapies for such diseases.
EXPERIMENTAL PROCEDURES
Mice RARg (Lohnes et al., 1993) 
Hematological Measurements and Phenotyping
Peripheral blood, BM, spleen, and thymic cell content were measured on a Sysmex K1000 Auto analyzer (Sysmex). Bone marrow, spleen, thymus, and hemolyzed PB cells were stained with antibodies to B lymphocytes (B220-PE and IgM-FITC), T lymphocytes (CD4-FITC and CD8a-PE), granulocytes (CD11b-PE and Gr-1-FITC), and erythrocytes (Ter119-PE) as previously described (Walkley et al., 2002) . Samples were analyzed on a FACSCAN (Becton Dickinson).
Histopathological and Immunohistochemical Analysis
Whole mice were presented for necropsy fixed in Bouin's fixative. Tissues from all major organ systems were collected, processed, sectioned, and stained with hematoxylin and eosin by routine methods. Tissue sections with spleen, liver, kidney, adipose, and BM were immunostained with myeloperoxidase (MPO; Abcam, Cambridge, MA) to identify myeloid cells. Briefly, sections were deparaffinized and dehydrated followed by antigen retrieval in Reveal Citra buffer (Biocare Medical, Walnut Creek, CA) using a pressurized antigen-decloaking chamber (Biocare). Sections were blocked with normal serum followed by an avidin block then incubated overnight at 4 C with a rabbit polyclonal MPO (pre-diluted). The sections were then blocked with biotin and incubated with biotinylated goat antirabbit (1:200) for 35 min at room temperature. Lastly sections were treated with streptavidin-peroxidase (Biogenix, San Ramon, CA), Romulan AEC chromagen (as per manufacturer's instructions), and counterstained with Richard-Allan hematoxylin.
Transplant Studies
Recipient mice were lethally irradiated with a total dose of 10 Gy, given in two equal fractions 3 hr apart, delivered by two opposing To assess potential leukemic transformation of the transplanted cells, spleen cells consisting of 2.5 3 10 6 leukocytes obtained from a RARg À/À recipient were transplanted into new lethally irradiated RARg À/À or wild-type recipients. PB cellularity, donor cell engraftment and hematopoietic cell content were analyzed 8 weeks post-BMT as described above.
Quantitation of Progenitor Cell Content in RARg Mutant Mice
Colony-forming cell assays were performed using BM, spleen and hemolzyed PB cells as previously described (Walkley et al., 2002) . Progenitor cell survival and cytokine responsiveness were measured as previously described (Walkley et al., 2002) . The numbers of common myeloid progenitors (CMPs), granulocyte/macrophage progenitors (GMPs) and megakaryocte/erythroid progenitors (MEPs) were assessed as previously described (Walkley et al., 2005) .
RNA extraction and Quantitative RT-PCR Extraction of mRNA, synthesis of cDNA and Q-RT-PCR were performed as previously described (Purton et al., 2006) . All primers used in these studies are given in Table S7 .
Statistics
The results are expressed as the mean ± standard error of the mean (SEM) for n given samples. Data were analyzed using the two-tailed Student's t test, with any p value less than or equal to 0.05 being considered significant.
Supplemental Data
Supplemental Data include four figures and seven tables, and can be found with this article online at http://www.cell.com/cgi/content/full/ 129/6/1097/DC1/.
